 Connection
Charles Daley to Drug Therapy, Combination
This is a "connection" page, showing publications Charles Daley has written about Drug Therapy, Combination.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.138 |
|
|
|
-
Daley CL, van Ingen J, Chalmers JD, Flume PA, Griffith DE, Hasegawa N, Morimoto K, Winthrop KL, Sheu CC, Avsar K, Andrisani D, Codecasa LR, Terschlüsen E, May D, Yuen DW, Wu P, Hassan M, Nevoret ML, Mange K. Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial. Ann Am Thorac Soc. 2026 Apr 01; 23(4):536-547.
Score: 0.192
-
Martiniano SL, Nick JA, Daley CL. Nontuberculous Mycobacterial Infections in Cystic Fibrosis. Clin Chest Med. 2022 12; 43(4):697-716.
Score: 0.153
-
Daley CL, Winthrop KL. Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management. J Infect Dis. 2020 08 20; 222(Suppl 4):S199-S211.
Score: 0.130
-
Koh WJ, Jeong BH, Jeon K, Park HY, Kim SY, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2015 Aug; 59(8):4994-6.
Score: 0.091
-
van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012 Sep 15; 186(6):559-65.
Score: 0.074
-
Kasperbauer SH, Daley CL. Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin Respir Crit Care Med. 2008 Oct; 29(5):569-76.
Score: 0.057
-
Saukkonen JJ, Duarte R, Munsiff SS, Winston CA, Mammen MJ, Abubakar I, Acuña-Villaorduña C, Barry PM, Bastos ML, Carr W, Chami H, Chen LL, Chorba T, Daley CL, Garcia-Prats AJ, Holland K, Konstantinidis I, Lipman M, Battista Migliori G, Parvez FM, Shapiro AE, Sotgiu G, Starke JR, Starks AM, Thakore S, Wang SH, Wortham JM, Nahid P. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2025 01; 211(1):15-33.
Score: 0.044
-
Shin E, Dousa KM, Taracila MA, Bethel CR, Nantongo M, Nguyen DC, Akusobi C, Kurz SG, Plummer MS, Daley CL, Holland SM, Rubin EJ, Bulitta JB, Boom WH, Kreiswirth BN, Bonomo RA. Durlobactam in combination with ß-lactams to combat Mycobacterium abscessus. Antimicrob Agents Chemother. 2025 02 13; 69(2):e0117424.
Score: 0.044
-
Marras TK, Morris A, Gonzalez LC, Daley CL. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med. 2004 Oct 01; 170(7):793-8.
Score: 0.043
-
Jasmer RM, Daley CL. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? Am J Respir Crit Care Med. 2003 Mar 15; 167(6):809-10.
Score: 0.039
-
Kang N, Jeon K, Kim H, Kwon OJ, Huh HJ, Lee NY, Daley CL, Koh WJ, Jhun BW. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease. Chest. 2021 08; 160(2):436-445.
Score: 0.034
-
Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 11 15; 200(10):e93-e142.
Score: 0.031
-
Moon SM, Choe J, Jhun BW, Jeon K, Kwon OJ, Huh HJ, Lee NY, Daley CL, Koh WJ. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. Respir Med. 2019 03; 148:37-42.
Score: 0.029
-
Jhun BW, Yang B, Moon SM, Lee H, Park HY, Jeon K, Kwon OJ, Ahn J, Moon IJ, Shin SJ, Daley CL, Koh WJ. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease. Antimicrob Agents Chemother. 2018 07; 62(7).
Score: 0.028
-
Koh WJ, Moon SM, Kim SY, Woo MA, Kim S, Jhun BW, Park HY, Jeon K, Huh HJ, Ki CS, Lee NY, Chung MJ, Lee KS, Shin SJ, Daley CL, Kim H, Kwon OJ. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017 09; 50(3).
Score: 0.027
-
Yang B, Jhun BW, Moon SM, Lee H, Park HY, Jeon K, Kim DH, Kim SY, Shin SJ, Daley CL, Koh WJ. Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease. Antimicrob Agents Chemother. 2017 06; 61(6).
Score: 0.026
-
Koh WJ, Jeong BH, Jeon K, Kim SY, Park KU, Park HY, Huh HJ, Ki CS, Lee NY, Lee SH, Kim CK, Daley CL, Shin SJ, Kim H, Kwon OJ. Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease. Chest. 2016 Dec; 150(6):1211-1221.
Score: 0.024
-
Jeong BH, Jeon K, Park HY, Kim SY, Lee KS, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015 Jan 01; 191(1):96-103.
Score: 0.022
-
Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Shin SJ, Huitt GA, Daley CL, Kwon OJ. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011 Feb 01; 183(3):405-10.
Score: 0.016
-
Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006 Aug 01; 174(3):331-8.
Score: 0.012
-
Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzaro A. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006 Jun 01; 173(11):1283-9.
Score: 0.012
-
Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002 Oct 15; 137(8):640-7.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|